On the other hand, HNSCC cell lines with SMAD4 homozygous deletion have been shown to exhibit sensitivity to olaparib, a well-studied PARP inhibitor, which appears to increase DNA damage and cell death in combination with RT in vivo [208]. This evidence concerns the gene PARP1 and head and neck squamous cell carcinoma.